{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["3CLPro", "PLPro", "SARS-CoV-2", "docking", "medicinal plants", "molecular dynamic simulations"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38474509", "DateCompleted": {"Year": "2024", "Month": "03", "Day": "14"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "15"}, "Article": {"Language": ["eng"], "ELocationID": ["998", "10.3390/molecules29050998"], "ArticleDate": [{"Year": "2024", "Month": "02", "Day": "25"}], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "29", "Issue": "5", "PubDate": {"Year": "2024", "Month": "Feb", "Day": "25"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Identification of Phytochemicals from Arabian Peninsula Medicinal Plants as Strong Binders to SARS-CoV-2 Proteases (3CL<sup>Pro</sup> and PL<sup>Pro</sup>) by Molecular Docking and Dynamic Simulation Studies.", "Abstract": {"AbstractText": ["We provide promising computational (in silico) data on phytochemicals (compounds <b>1</b>-<b>10</b>) from Arabian Peninsula medicinal plants as strong binders, targeting 3-chymotrypsin-like protease (3CL<sup>Pro</sup>) and papain-like proteases (PL<sup>Pro</sup>) of SARS-CoV-2. Compounds <b>1</b>-<b>10</b> followed the Lipinski rules of five (RO5) and ADMET analysis, exhibiting drug-like characters. Non-covalent (reversible) docking of compounds <b>1</b>-<b>10</b> demonstrated their binding with the catalytic dyad (CYS145 and HIS41) of 3CL<sup>Pro</sup> and catalytic triad (CYS111, HIS272, and ASP286) of PL<sup>Pro</sup>. Moreover, the implementation of the covalent (irreversible) docking protocol revealed that only compounds <b>7</b>, <b>8</b>, and <b>9</b> possess covalent warheads, which allowed the formation of the covalent bond with the catalytic dyad (CYS145) in 3CL<sup>Pro</sup> and the catalytic triad (CYS111) in PL<sup>Pro</sup>. Root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and radius of gyration (Rg) analysis from molecular dynamic (MD) simulations revealed that complexation between ligands (compounds <b>7</b>, <b>8</b>, and <b>9</b>) and 3CL<sup>Pro</sup> and PL<sup>Pro</sup> was stable, and there was less deviation of ligands. Overall, the in silico data on the inherent properties of the above phytochemicals unravel the fact that they can act as reversible inhibitors for 3CL<sup>Pro</sup> and PL<sup>Pro</sup>. Moreover, compounds <b>7</b>, <b>8</b>, and <b>9</b> also showed their novel properties to inhibit dual targets by irreversible inhibition, indicating their effectiveness for possibly developing future drugs against SARS-CoV-2. Nonetheless, to confirm the theoretical findings here, the effectiveness of the above compounds as inhibitors of 3CL<sup>Pro</sup> and PL<sup>Pro</sup> warrants future investigations using suitable in vitro and in vivo tests."]}, "AuthorList": [{"Identifier": ["0000-0001-7030-3777"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}], "LastName": "Saquib", "ForeName": "Quaiser", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia."}], "LastName": "Bakheit", "ForeName": "Ahmed H", "Initials": "AH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia."}], "LastName": "Ahmed", "ForeName": "Sarfaraz", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Botany & Microbiology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}], "LastName": "Ansari", "ForeName": "Sabiha M", "Initials": "SM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}], "LastName": "Al-Salem", "ForeName": "Abdullah M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, College of Sciences, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia."}], "LastName": "Al-Khedhairy", "ForeName": "Abdulaziz A", "Initials": "AA"}], "GrantList": [{"GrantID": "This research was funded by King Abdulaziz City for Science and Technology (KACST) via the Fast Track Funding Path for COVID-19 Research Projects, grant number 5-21-01-001-0025.", "Agency": "King Abdulaziz City for Science and Technology", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "EC 3.4.-", "NameOfSubstance": "Peptide Hydrolases"}, {"RegistryNumber": "EC 3.4.22.2", "NameOfSubstance": "Papain"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protease Inhibitors"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Peptide Hydrolases"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "Papain"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": [], "DescriptorName": "Phytochemicals"}, {"QualifierName": [], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Protease Inhibitors"}], "CoiStatement": "The authors declare no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "WHO  WHO Coronavirus (COVID-19) Dashboard. 2023.  [(accessed on 22 November 2023)].  Available online:  https://covid19.who.int."}, {"Citation": "Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S.C., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708\u20131720. doi: 10.1056/NEJMoa2002032.", "ArticleIdList": ["10.1056/NEJMoa2002032", "PMC7092819", "32109013"]}, {"Citation": "Bi Q., Wu Y., Mei S., Ye C., Zou X., Zhang Z., Liu X., Wei L., Truelove S.A., Zhang T., et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. Lancet Infect. Dis. 2020;20:911\u2013919. doi: 10.1016/S1473-3099(20)30287-5.", "ArticleIdList": ["10.1016/S1473-3099(20)30287-5", "PMC7185944", "32353347"]}, {"Citation": "Monteleone G., Sarzi-Puttini P.C., Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol. 2020;2:e255\u2013e256. doi: 10.1016/S2665-9913(20)30092-8.", "ArticleIdList": ["10.1016/S2665-9913(20)30092-8", "PMC7193140", "32368737"]}, {"Citation": "Amaral-Machado L., Oliveira W.N., Rodrigues V.M., Albuquerque N.A., Alencar \u00c9.N., Egito E.S.T. Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients? Biomed. Pharmacother. 2021;134:111143. doi: 10.1016/j.biopha.2020.111143.", "ArticleIdList": ["10.1016/j.biopha.2020.111143", "PMC7832252", "33360048"]}, {"Citation": "Li X., Geng M., Peng Y., Meng L., Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. 2020;10:102\u2013108. doi: 10.1016/j.jpha.2020.03.001.", "ArticleIdList": ["10.1016/j.jpha.2020.03.001", "PMC7104082", "32282863"]}, {"Citation": "Das G., Das T., Chowdhury N., Chatterjee D., Bagchi A., Ghosh Z. Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19. Genomics. 2021;113:1129\u20131140. doi: 10.1016/j.ygeno.2020.11.009.", "ArticleIdList": ["10.1016/j.ygeno.2020.11.009", "PMC7661923", "33189776"]}, {"Citation": "Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66\u201370. doi: 10.1016/j.cytogfr.2020.05.002.", "ArticleIdList": ["10.1016/j.cytogfr.2020.05.002", "PMC7204669", "32418715"]}, {"Citation": "Fehr A.R., Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. In: Maier H.J., Bickerton E., Britton P., editors. Coronaviruses: Methods and Protocols. Springer New York; New York, NY, USA: 2015. pp. 1\u201323.", "ArticleIdList": ["10.1007/978-1-4939-2438-7_1", "PMC4369385", "25720466"]}, {"Citation": "Jade D., Ayyamperumal S., Tallapaneni V., Joghee Nanjan C.M., Barge S., Mohan S., Nanjan M.J. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PLPRO and 3CLPRO proteases. Eur. J. Pharmacol. 2021;901:174082. doi: 10.1016/j.ejphar.2021.174082.", "ArticleIdList": ["10.1016/j.ejphar.2021.174082", "PMC8018918", "33823185"]}, {"Citation": "Tumskiy R.S., Tumskaia A.V., Klochkova I.N., Richardson R.J. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations. Comput. Biol. Med. 2023;153:106449. doi: 10.1016/j.compbiomed.2022.106449.", "ArticleIdList": ["10.1016/j.compbiomed.2022.106449", "PMC9788855", "36586228"]}, {"Citation": "Nesterenko P.A., McLaughlin J., Tsai B.L., Burton Sojo G., Cheng D., Zhao D., Mao Z., Bangayan N.J., Obusan M.B., Su Y., et al. HLA-A\u221702:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. Cell Rep. 2021;37:110167. doi: 10.1016/j.celrep.2021.110167.", "ArticleIdList": ["10.1016/j.celrep.2021.110167", "PMC8660260", "34919800"]}, {"Citation": "Zhang L.-c., Zhao H.-l., Liu J., He L., Yu R.-l., Kang C.-m. Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening. Future Med. Chem. 2022;14:393\u2013405. doi: 10.4155/fmc-2021-0269.", "ArticleIdList": ["10.4155/fmc-2021-0269", "PMC8920029", "35220726"]}, {"Citation": "Lin C.-W., Tsai F.-J., Tsai C.-H., Lai C.-C., Wan L., Ho T.-Y., Hsieh C.-C., Chao P.-D.L. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antivir. Res. 2005;68:36\u201342. doi: 10.1016/j.antiviral.2005.07.002.", "ArticleIdList": ["10.1016/j.antiviral.2005.07.002", "PMC7114321", "16115693"]}, {"Citation": "Prasansuklab A., Theerasri A., Rangsinth P., Sillapachaiyaporn C., Chuchawankul S., Tencomnao T. Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection. J. Tradit. Complement. Med. 2020;11:144\u2013157. doi: 10.1016/j.jtcme.2020.12.001.", "ArticleIdList": ["10.1016/j.jtcme.2020.12.001", "PMC7833040", "33520683"]}, {"Citation": "Morse J.S., Lalonde T., Xu S., Liu W.R. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem. 2020;21:730\u2013738. doi: 10.1002/cbic.202000047.", "ArticleIdList": ["10.1002/cbic.202000047", "PMC7162020", "32022370"]}, {"Citation": "Deng W., Xu Y., Kong Q., Xue J., Yu P., Liu J., Lv Q., Li F., Wei Q., Bao L. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo. Signal Transduct. Target. Ther. 2020;5:66. doi: 10.1038/s41392-020-0176-0.", "ArticleIdList": ["10.1038/s41392-020-0176-0", "PMC7205908", "32385228"]}, {"Citation": "Ni L., Zhou L., Zhou M., Zhao J., Wang D.W. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19. Front. Med. 2020;14:210\u2013214. doi: 10.1007/s11684-020-0757-x.", "ArticleIdList": ["10.1007/s11684-020-0757-x", "PMC7088740", "32170559"]}, {"Citation": "Schettig R., Sears T., Klein M., Tan-Lim R., Matthias R., Jr., Aussems C., Hummel M., Sears R., Poteet Z., Warren D. COVID-19 Patient with Multifocal Pneumonia and Respiratory Difficulty Resolved Quickly: Possible Antiviral and Anti-Inflammatory Benefits of Quercinex (Nebulized Quercetin-NAC) as Adjuvant. Adv. Infect. Dis. 2020;10:45\u201355. doi: 10.4236/aid.2020.103006.", "ArticleIdList": ["10.4236/aid.2020.103006"]}, {"Citation": "Dai Y., Qiang W., Gui Y., Tan X., Pei T., Lin K., Cai S., Sun L., Ning G., Wang J., et al. A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional chinese medicines. Sci. Bull. 2021;66:884\u2013888. doi: 10.1016/j.scib.2021.01.005.", "ArticleIdList": ["10.1016/j.scib.2021.01.005", "PMC7803147", "33457042"]}, {"Citation": "Tsai K.C., Huang Y.C., Liaw C.C., Tsai C.I., Chiou C.T., Lin C.J., Wei W.C., Lin S.J., Tseng Y.H., Yeh K.M., et al. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed. Pharmacother. 2021;133:111037. doi: 10.1016/j.biopha.2020.111037.", "ArticleIdList": ["10.1016/j.biopha.2020.111037", "PMC7676327", "33249281"]}, {"Citation": "Shang Z.P., Yi Y., Yu R., Fan J.J., Huang Y.X., Qiao X., Ye M. [Bioactive compounds of Jingfang Granules against SARS-CoV-2 virus proteases 3CL(pro) and PL(pro)] Beijing Da Xue Xue Bao Yi Xue Ban. 2022;54:907\u2013919. doi: 10.19723/j.issn.1671-167X.2022.05.018.", "ArticleIdList": ["10.19723/j.issn.1671-167X.2022.05.018", "PMC9568378", "36241233"]}, {"Citation": "Guijarro-Real C., Plazas M., Rodr\u00edguez-Burruezo A., Prohens J., Fita A. Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity. Foods. 2021;10:1503. doi: 10.3390/foods10071503.", "ArticleIdList": ["10.3390/foods10071503", "PMC8304378", "34209659"]}, {"Citation": "\u00c1vila-G\u00e1lvez M.\u00c1., Rafael-Pita C., Fern\u00e1ndez N., Baixinho J., Anast\u00e1cio J.D., Cankar K., Bosch D., Nunes dos Santos C. Targeting proteases involved in the viral replication of SARS-CoV-2 by sesquiterpene lactones from chicory (Cichorium intybus L.) Food Funct. 2022;13:8977\u20138988. doi: 10.1039/D2FO00933A.", "ArticleIdList": ["10.1039/D2FO00933A", "35938740"]}, {"Citation": "Mar\u00edn-Palma D., Tabares-Guevara J.H., Zapata-Cardona M.I., Fl\u00f3rez-\u00c1lvarez L., Yepes L.M., Rugeles M.T., Zapata-Builes W., Hernandez J.C., Taborda N.A. Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms. Molecules. 2021;26:6900. doi: 10.3390/molecules26226900.", "ArticleIdList": ["10.3390/molecules26226900", "PMC8618354", "34833991"]}, {"Citation": "Di Pierro F., Derosa G., Maffioli P., Bertuccioli A., Togni S., Riva A., Allegrini P., Khan A., Khan S., Khan B.A., et al. Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. Int. J. Gen. Med. 2021;14:2359\u20132366. doi: 10.2147/IJGM.S318720.", "ArticleIdList": ["10.2147/IJGM.S318720", "PMC8197660", "34135619"]}, {"Citation": "Jo S., Kim S., Shin D.H., Kim M.S. Inhibition of SARS-CoV 3CL protease by flavonoids. J. Enzym. Inhib. Med. Chem. 2020;35:145\u2013151. doi: 10.1080/14756366.2019.1690480.", "ArticleIdList": ["10.1080/14756366.2019.1690480", "PMC6882434", "31724441"]}, {"Citation": "Milanovi\u0107 \u017d B., Antonijevi\u0107 M.R., Ami\u0107 A.D., Avdovi\u0107 E.H., Dimi\u0107 D.S., Milenkovi\u0107 D.A., Markovi\u0107 Z.S. Inhibitory activity of quercetin, its metabolite, and standard antiviral drugs towards enzymes essential for SARS-CoV-2: The role of acid-base equilibria. RSC Adv. 2021;11:2838\u20132847. doi: 10.1039/D0RA09632F.", "ArticleIdList": ["10.1039/D0RA09632F", "PMC8693803", "35424215"]}, {"Citation": "Barhouchi B., Menacer R., Bouchkioua S., Mansour A., Belattar N. Compounds from myrtle flowers as antibacterial agents and SARS-CoV-2 inhibitors: In-vitro and molecular docking studies. Arab. J. Plant Prot. 2023;16:104939. doi: 10.1016/j.arabjc.2023.104939.", "ArticleIdList": ["10.1016/j.arabjc.2023.104939", "PMC10140470", "37193561"]}, {"Citation": "Guimar\u00e3es Santana B.C., de Almeida Marques D.P., dos Santos Freitas A., Ferreira M.M., de Sousa Lopes D., Bagno F.F., Guimar\u00e3es da Fonseca F., dos Reis J.G.A.C., Oliveira Mendes T.A.d., Santos J.L.d., et al. Protease inhibitors from Theobroma cacao impair SARS-CoV-2 replication in vitro. Heliyon. 2023;9:e15860. doi: 10.1016/j.heliyon.2023.e15860.", "ArticleIdList": ["10.1016/j.heliyon.2023.e15860", "PMC10155420", "37153407"]}, {"Citation": "Hossain A., Rahman M.E., Rahman M.S., Nasirujjaman K., Matin M.N., Faruqe M.O., Rabbee M.F. Identification of medicinal plant-based phytochemicals as a potential inhibitor for SARS-CoV-2 main protease (Mpro) using molecular docking and deep learning methods. Comput. Biol. Med. 2023;157:106785. doi: 10.1016/j.compbiomed.2023.106785.", "ArticleIdList": ["10.1016/j.compbiomed.2023.106785", "PMC10008098", "36931201"]}, {"Citation": "Zhang Y.-N., Zhu G.-H., Liu W., Xiong Y., Hu Q., Zhuang X.-Y., Jia G.-H., Zhang W.-D., Ge G.-B. Discovery and characterization of the covalent SARS-CoV-2 3CLpro inhibitors from Ginkgo biloba extract via integrating chemoproteomic and biochemical approaches. Phytomedicine. 2023;114:154796. doi: 10.1016/j.phymed.2023.154796.", "ArticleIdList": ["10.1016/j.phymed.2023.154796", "PMC10052880", "37037086"]}, {"Citation": "Ahmed S., Al-Rehaily A.J., Ahmad M.S., Yousaf M., Nur-e-Alam M., Parvez M.K., Al-Dosari M.S., Noman O.M., Khan S.I., Khan I.A. Chemical constituents from Oncocalyx glabratus and their biological activities. Phytochem. Lett. 2017;20:128\u2013132. doi: 10.1016/j.phytol.2017.04.016.", "ArticleIdList": ["10.1016/j.phytol.2017.04.016"]}, {"Citation": "Ahmed S., Al-Rehaily A.J., Ahmad M.S., Yousaf M., Nur-e-Alam M., Thomas J., Khan S.I., Khan I.A. Cytotoxic and antiinflammatory activities of the chemical constituents isolated from Baccharoides schimperi DC. S. Afr. J. Bot. 2018;114:9\u201313. doi: 10.1016/j.sajb.2017.10.007.", "ArticleIdList": ["10.1016/j.sajb.2017.10.007"]}, {"Citation": "Ahmed S., Mothana R., Yousaf M., Al-Rehaily A. Activity guided isolation of chemical constituents from the biologically active methanol extract of Euphorbia schimperi C. Presl. Bull. Chem. Soc. Ethiop. 2017;31:471\u2013479. doi: 10.4314/bcse.v31i3.11.", "ArticleIdList": ["10.4314/bcse.v31i3.11"]}, {"Citation": "Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289\u2013293. doi: 10.1038/s41586-020-2223-y.", "ArticleIdList": ["10.1038/s41586-020-2223-y", "32272481"]}, {"Citation": "Hakami A.R., Bakheit A.H., Almehizia A.A., Ghazwani M.Y. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening. Future Med. Chem. 2021;14:61\u201379. doi: 10.4155/fmc-2020-0380.", "ArticleIdList": ["10.4155/fmc-2020-0380", "PMC8612299", "34814706"]}, {"Citation": "Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science. 2020;368:409\u2013412. doi: 10.1126/science.abb3405.", "ArticleIdList": ["10.1126/science.abb3405", "PMC7164518", "32198291"]}, {"Citation": "Sanachai K., Mahalapbutr P., Sanghiran Lee V., Rungrotmongkol T., Hannongbua S. In Silico Elucidation of Potent Inhibitors and Rational Drug Design against SARS-CoV-2 Papain-like Protease. J. Phys. Chem. B. 2021;125:13644\u201313656. doi: 10.1021/acs.jpcb.1c07060.", "ArticleIdList": ["10.1021/acs.jpcb.1c07060", "34904832"]}, {"Citation": "Bakheit A.H., Attwa M.W., Kadi A.A., Alkahtani H.M. Structural Analysis and Reactivity Insights of (E)-Bromo-4-((4-((1-(4-chlorophenyl)ethylidene)amino)-5-phenyl-4H-1,2,4-triazol-3-yl)thio)-5-((2-isopropylcyclohexyl)oxy) Furan-2(5H)-one: A Combined Approach Using Single-Crystal X-ray Diffraction, Hirshfeld Surface Analysis, and Conceptual Density Functional Theory. Crystals. 2023;13:1313."}, {"Citation": "Hognon C., Marazzi M., Garc\u00eda-Iriepa C. Atomistic-Level Description of the Covalent Inhibition of SARS-CoV-2 Papain-like Protease. Int. J. Mol. Sci. 2022;23:5855. doi: 10.3390/ijms23105855.", "ArticleIdList": ["10.3390/ijms23105855", "PMC9143025", "35628665"]}, {"Citation": "Amin S.A., Banerjee S., Ghosh K., Gayen S., Jha T. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Biorg. Med. Chem. 2021;29:115860. doi: 10.1016/j.bmc.2020.115860.", "ArticleIdList": ["10.1016/j.bmc.2020.115860", "PMC7647411", "33191083"]}, {"Citation": "Shen Z., Ratia K., Cooper L., Kong D., Lee H., Kwon Y., Li Y., Alqarni S., Huang F., Dubrovskyi O., et al. Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. J. Med. Chem. 2022;65:2940\u20132955. doi: 10.1021/acs.jmedchem.1c01307.", "ArticleIdList": ["10.1021/acs.jmedchem.1c01307", "PMC8547495", "34665619"]}, {"Citation": "Liu Y., Liang C., Xin L., Ren X., Tian L., Ju X., Li H., Wang Y., Zhao Q., Liu H., et al. The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020. Eur. J. Med. Chem. 2020;206:112711. doi: 10.1016/j.ejmech.2020.112711.", "ArticleIdList": ["10.1016/j.ejmech.2020.112711", "PMC7409838", "32810751"]}, {"Citation": "Lei J., Kusov Y., Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antivir. Res. 2018;149:58\u201374. doi: 10.1016/j.antiviral.2017.11.001.", "ArticleIdList": ["10.1016/j.antiviral.2017.11.001", "PMC7113668", "29128390"]}, {"Citation": "Woo P.C.Y., Huang Y., Lau S.K.P., Yuen K.-Y. Coronavirus Genomics and Bioinformatics Analysis. Viruses. 2010;2:1804\u20131820. doi: 10.3390/v2081803.", "ArticleIdList": ["10.3390/v2081803", "PMC3185738", "21994708"]}, {"Citation": "Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar Andrew D., Baker Susan C. The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Activity. J. Virol. 2005;79:15189\u201315198. doi: 10.1128/JVI.79.24.15189-15198.2005.", "ArticleIdList": ["10.1128/JVI.79.24.15189-15198.2005", "PMC1316023", "16306590"]}, {"Citation": "B\u00e1ez-Santos Y.M., St. John S.E., Mesecar A.D. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antivir. Res. 2015;115:21\u201338. doi: 10.1016/j.antiviral.2014.12.015.", "ArticleIdList": ["10.1016/j.antiviral.2014.12.015", "PMC5896749", "25554382"]}, {"Citation": "Osipiuk J., Azizi S.-A., Dvorkin S., Endres M., Jedrzejczak R., Jones K.A., Kang S., Kathayat R.S., Kim Y., Lisnyak V.G., et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 2021;12:743. doi: 10.1038/s41467-021-21060-3.", "ArticleIdList": ["10.1038/s41467-021-21060-3", "PMC7854729", "33531496"]}, {"Citation": "Csermely P., \u00c1goston V., Pongor S. The efficiency of multi-target drugs: The network approach might help drug design. Trends Pharmacol. Sci. 2005;26:178\u2013182. doi: 10.1016/j.tips.2005.02.007.", "ArticleIdList": ["10.1016/j.tips.2005.02.007", "15808341"]}, {"Citation": "Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings1PII of original article: S0169-409X(96)00423-1. The article was originally published in Adv. Drug Deliv. Rev. 1997, 23, 3\u201325. Adv. Drug Del. Rev. 2001;46:3\u201326. doi: 10.1016/S0169-409X(00)00129-0.", "ArticleIdList": ["10.1016/S0169-409X(00)00129-0", "11259830"]}, {"Citation": "Lipinski C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 2004;1:337\u2013341. doi: 10.1016/j.ddtec.2004.11.007.", "ArticleIdList": ["10.1016/j.ddtec.2004.11.007", "24981612"]}, {"Citation": "Padhi S., Masi M., Chourasia R., Rajashekar Y., Rai A.K., Evidente A. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors. Eur. J. Pharmacol. 2021;890:173648. doi: 10.1016/j.ejphar.2020.173648.", "ArticleIdList": ["10.1016/j.ejphar.2020.173648", "PMC7561576", "33069672"]}, {"Citation": "Halder S.K., Sultana I., Shuvo M.N., Shil A., Himel M.K., Hasan M.A., Shawan M. In Silico Identification and Analysis of Potentially Bioactive Antiviral Phytochemicals against SARS-CoV-2: A Molecular Docking and Dynamics Simulation Approach. BioMed Res. Int. 2023;2023:5469258. doi: 10.1155/2023/5469258.", "ArticleIdList": ["10.1155/2023/5469258", "PMC10195178", "37214084"]}, {"Citation": "Khanal P., Patil V.S., Bhandare V.V., Dwivedi P.S.R., Shastry C.S., Patil B.M., Gurav S.S., Harish D.R., Roy S. Computational investigation of benzalacetophenone derivatives against SARS-CoV-2 as potential multi-target bioactive compounds. Comput. Biol. Med. 2022;146:105668. doi: 10.1016/j.compbiomed.2022.105668.", "ArticleIdList": ["10.1016/j.compbiomed.2022.105668", "PMC9135652", "35667894"]}, {"Citation": "Mosquera-Yuqui F., Lopez-Guerra N., Moncayo-Palacio E.A. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: Molecular docking and molecular dynamics simulations. J. Biomol. Struct. Dyn. 2022;40:2010\u20132023. doi: 10.1080/07391102.2020.1835716.", "ArticleIdList": ["10.1080/07391102.2020.1835716", "PMC7657401", "33084512"]}, {"Citation": "Du X., Li Y., Xia Y.-L., Ai S.-M., Liang J., Sang P., Ji X.-L., Liu S.-Q. Insights into Protein\u2013Ligand Interactions: Mechanisms, Models, and Methods. Int. J. Mol. Sci. 2016;17:144. doi: 10.3390/ijms17020144.", "ArticleIdList": ["10.3390/ijms17020144", "PMC4783878", "26821017"]}, {"Citation": "Koulgi S., Jani V., Uppuladinne V.N.M., Sonavane U., Joshi R. Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2. PLoS ONE. 2021;16:e0251801. doi: 10.1371/journal.pone.0251801.", "ArticleIdList": ["10.1371/journal.pone.0251801", "PMC8118514", "33984041"]}, {"Citation": "Kawall A., Lewis D.S.M., Sharma A., Chavada K., Deshmukh R., Rayalam S., Mody V., Taval S. Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity. Front. Chem. 2023;10:1100460. doi: 10.3389/fchem.2022.1100460.", "ArticleIdList": ["10.3389/fchem.2022.1100460", "PMC9878345", "36712981"]}, {"Citation": "Pillaiyar T., Manickam M., Namasivayam V., Hayashi Y., Jung S.-H. An Overview of Severe Acute Respiratory Syndrome\u2013Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. J. Med. Chem. 2016;59:6595\u20136628. doi: 10.1021/acs.jmedchem.5b01461.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01461", "PMC7075650", "26878082"]}, {"Citation": "Tang B., He F., Liu D., He F., Wu T., Fang M., Niu Z., Wu Z., Xu D. AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2. Biomolecules. 2022;12:746. doi: 10.3390/biom12060746.", "ArticleIdList": ["10.3390/biom12060746", "PMC9220321", "35740872"]}, {"Citation": "Gehringer M., Laufer S.A. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. J. Med. Chem. 2019;62:5673\u20135724. doi: 10.1021/acs.jmedchem.8b01153.", "ArticleIdList": ["10.1021/acs.jmedchem.8b01153", "30565923"]}, {"Citation": "Huang F., Han X., Xiao X., Zhou J. Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development. Molecules. 2022;27:7728. doi: 10.3390/molecules27227728.", "ArticleIdList": ["10.3390/molecules27227728", "PMC9694382", "36431829"]}, {"Citation": "Liang S.T., Chen C., Chen R.X., Li R., Chen W.L., Jiang G.H., Du L.L. Michael acceptor molecules in natural products and their mechanism of action. Front. Pharmacol. 2022;13:1033003. doi: 10.3389/fphar.2022.1033003.", "ArticleIdList": ["10.3389/fphar.2022.1033003", "PMC9666775", "36408214"]}, {"Citation": "Zmudzinski M., Rut W., Olech K., Granda J., Giurg M., Burda-Grabowska M., Kaleta R., Zgarbova M., Kasprzyk R., Zhang L., et al. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase. Sci. Rep. 2023;13:9161. doi: 10.1038/s41598-023-35907-w.", "ArticleIdList": ["10.1038/s41598-023-35907-w", "PMC10242237", "37280236"]}, {"Citation": "Rut W., Lv Z., Zmudzinski M., Patchett S., Nayak D., Snipas S.J., El Oualid F., Huang T.T., Bekes M., Drag M., et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti\u2013COVID-19 drug design. Sci. Adv. 2020;6:eabd4596. doi: 10.1126/sciadv.abd4596.", "ArticleIdList": ["10.1126/sciadv.abd4596", "PMC7567588", "33067239"]}, {"Citation": "Gao X., Qin B., Chen P., Zhu K., Hou P., Wojdyla J.A., Wang M., Cui S. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm. Sin. B. 2021;11:237\u2013245. doi: 10.1016/j.apsb.2020.08.014.", "ArticleIdList": ["10.1016/j.apsb.2020.08.014", "PMC7467110", "32895623"]}, {"Citation": "Klemm T., Ebert G., Calleja D.J., Allison C.C., Richardson L.W., Bernardini J.P., Lu B.G.C., Kuchel N.W., Grohmann C., Shibata Y., et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J. 2020;39:e106275. doi: 10.15252/embj.2020106275.", "ArticleIdList": ["10.15252/embj.2020106275", "PMC7461020", "32845033"]}, {"Citation": "Ivanov J., Polshakov D., Kato-Weinstein J., Zhou Q., Li Y., Granet R., Garner L., Deng Y., Liu C., Albaiu D., et al. Quantitative Structure\u2013Activity Relationship Machine Learning Models and their Applications for Identifying Viral 3CLpro- and RdRp-Targeting Compounds as Potential Therapeutics for COVID-19 and Related Viral Infections. ACS Omega. 2020;5:27344\u201327358. doi: 10.1021/acsomega.0c03682.", "ArticleIdList": ["10.1021/acsomega.0c03682", "PMC7571315", "33134697"]}, {"Citation": "Welker A., Kersten C., M\u00fcller C., Madhugiri R., Zimmer C., M\u00fcller P., Zimmermann R., Hammerschmidt S., Maus H., Ziebuhr J., et al. Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2. ChemMedChem. 2021;16:340\u2013354. doi: 10.1002/cmdc.202000548.", "ArticleIdList": ["10.1002/cmdc.202000548", "PMC7894572", "32930481"]}, {"Citation": "Kumar V., Roy K. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. SAR QSAR Environ. Res. 2020;31:511\u2013526. doi: 10.1080/1062936X.2020.1776388.", "ArticleIdList": ["10.1080/1062936X.2020.1776388", "32543892"]}, {"Citation": "Gao H., Dai R., Su R. Computer-aided drug design for the pain-like protease (PLpro) inhibitors against SARS-CoV-2. Biomed. Pharmacother. 2023;159:114247. doi: 10.1016/j.biopha.2023.114247.", "ArticleIdList": ["10.1016/j.biopha.2023.114247", "PMC9841087", "36689835"]}, {"Citation": "Pitera J.W. Expected Distributions of Root-Mean-Square Positional Deviations in Proteins. J. Phys. Chem. B. 2014;118:6526\u20136530. doi: 10.1021/jp412776d.", "ArticleIdList": ["10.1021/jp412776d", "24655018"]}, {"Citation": "Azeem M., Mustafa G., Mahrosh H.S. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies. Int. J. Immunopathol. Pharmacol. 2022;36:03946320221142793. doi: 10.1177/03946320221142793.", "ArticleIdList": ["10.1177/03946320221142793", "PMC9716588", "36442514"]}, {"Citation": "Bornot A., Etchebest C., de Brevern A.G. Predicting protein flexibility through the prediction of local structures. Proteins Struct. Funct. Bioinform. 2011;79:839\u2013852. doi: 10.1002/prot.22922.", "ArticleIdList": ["10.1002/prot.22922", "PMC3317885", "21287616"]}, {"Citation": "Al-Otaibi J.S., Sheena Mary Y., Shyma Mary Y., Acharjee N., Balachandar S., Yathirajan H.S. Insights into solvation effects, spectroscopic, Hirshfeld surface Analysis, reactivity analysis and anti-Covid-19 ability of doxylamine succinate: Experimental, DFT, MD and docking simulations. J. Mol. Liq. 2022;361:119609. doi: 10.1016/j.molliq.2022.119609.", "ArticleIdList": ["10.1016/j.molliq.2022.119609"]}, {"Citation": "Ghazwani M.Y., Bakheit A.H., Hakami A.R., Alkahtani H.M., Almehizia A.A. Virtual Screening and Molecular Docking Studies for Discovery of Potential RNA-Dependent RNA Polymerase Inhibitors. Crystals. 2021;11:471. doi: 10.3390/cryst11050471.", "ArticleIdList": ["10.3390/cryst11050471"]}, {"Citation": "Weng Y.L., Naik S.R., Dingelstad N., Lugo M.R., Kalyaanamoorthy S., Ganesan A. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity. Sci. Rep. 2021;11:7429. doi: 10.1038/s41598-021-86471-0.", "ArticleIdList": ["10.1038/s41598-021-86471-0", "PMC8016996", "33795718"]}, {"Citation": "Parihar A., Sonia Z.F., Akter F., Ali M.A., Hakim F.T., Hossain M.S. Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: A promising therapeutic approach for Tackling COVID-19. Comput. Biol. Med. 2022;145:105468. doi: 10.1016/j.compbiomed.2022.105468.", "ArticleIdList": ["10.1016/j.compbiomed.2022.105468", "PMC8964014", "35390745"]}, {"Citation": "ChemAxon.  [(accessed on 3 September 2023)].  Available online:  https://chemaxon.com/marvin."}, {"Citation": "Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 2002;45:2615\u20132623. doi: 10.1021/jm020017n.", "ArticleIdList": ["10.1021/jm020017n", "12036371"]}, {"Citation": "ProTox-II\u2014Prediction of Toxicity of Chemicals.  [(accessed on 3 September 2023)].  Available online:  https://tox-new.charite.de/protox_II/"}, {"Citation": "Daina A., Michielin O., Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7:42717. doi: 10.1038/srep42717.", "ArticleIdList": ["10.1038/srep42717", "PMC5335600", "28256516"]}, {"Citation": "Mesecar A.D. Structure of COVID-19 main protease bound to potent broad-spectrum non-covalent inhibitor X77. Protein Data Bank. 2020 doi: 10.2210/pdb6W63/pdb.", "ArticleIdList": ["10.2210/pdb6W63/pdb"]}, {"Citation": "Khalaf H.S., Naglah A.M., Al-Omar M.A., Moustafa G.O., Awad H.M., Bakheit A.H. Synthesis, Docking, Computational Studies, and Antimicrobial Evaluations of New Dipeptide Derivatives Based on Nicotinoylglycylglycine Hydrazide. Molecules. 2020;25:3589. doi: 10.3390/molecules25163589.", "ArticleIdList": ["10.3390/molecules25163589", "PMC7464391", "32784576"]}, {"Citation": "Al-Khodairy F.M., Khan M.K.A., Kunhi M., Pulicat M.S., Akhtar S., Arif J.M. In Silico prediction of mechanism of Erysolin-induced apoptosis in human breast cancer cell lines. Am. J. Bioinform. Res. 2013;3:62\u201371."}, {"Citation": "Labute P. Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures. Proteins: Struct. Funct. Bioinform. 2009;75:187\u2013205. doi: 10.1002/prot.22234.", "ArticleIdList": ["10.1002/prot.22234", "PMC3056144", "18814299"]}, {"Citation": "Cuesta A., Wan X., Burlingame A.L., Taunton J. Ligand Conformational Bias Drives Enantioselective Modification of a Surface-Exposed Lysine on Hsp90. J. Am. Chem. Soc. 2020;142:3392\u20133400. doi: 10.1021/jacs.9b09684.", "ArticleIdList": ["10.1021/jacs.9b09684", "32009391"]}, {"Citation": "Wojciechowski M., Lesyng B. Generalized Born Model:\u2009 Analysis, Refinement, and Applications to Proteins. J. Phys. Chem. B. 2004;108:18368\u201318376. doi: 10.1021/jp046748b.", "ArticleIdList": ["10.1021/jp046748b"]}, {"Citation": "Corbeil C.R., Williams C.I., Labute P. Variability in docking success rates due to dataset preparation. J. Comput.-Aided Mol. Des. 2012;26:775\u2013786. doi: 10.1007/s10822-012-9570-1.", "ArticleIdList": ["10.1007/s10822-012-9570-1", "PMC3397132", "22566074"]}, {"Citation": "Na\u00efm M., Bhat S., Rankin K.N., Dennis S., Chowdhury S.F., Siddiqi I., Drabik P., Sulea T., Bayly C.I., Jakalian A., et al. Solvated Interaction Energy (SIE) for Scoring Protein\u2212Ligand Binding Affinities. 1. Exploring the Parameter Space. J. Chem. Inf. Model. 2007;47:122\u2013133. doi: 10.1021/ci600406v.", "ArticleIdList": ["10.1021/ci600406v", "17238257"]}, {"Citation": "Ghufran M., Ullah M., Khan H.A., Ghufran S., Ayaz M., Siddiq M., Abbas S.Q., Hassan S.S., Bungau S. In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations. Bioengineering. 2023;10:100. doi: 10.3390/bioengineering10010100.", "ArticleIdList": ["10.3390/bioengineering10010100", "PMC9854631", "36671672"]}, {"Citation": "Gao Y., Lee J., Smith I.P.S., Lee H., Kim S., Qi Y., Klauda J.B., Widmalm G., Khalid S., Im W. CHARMM-GUI Supports Hydrogen Mass Repartitioning and Different Protonation States of Phosphates in Lipopolysaccharides. J. Chem. Inf. Model. 2021;61:831\u2013839. doi: 10.1021/acs.jcim.0c01360.", "ArticleIdList": ["10.1021/acs.jcim.0c01360", "PMC7902386", "33442985"]}, {"Citation": "CHARMM General Force Field (CGenFF)  [(accessed on 3 September 2023)].  Available online:  https://cgenff.silcsbio.com."}, {"Citation": "Yu W., He X., Vanommeslaeghe K., MacKerell A.D., Jr. Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations. J. Comput. Chem. 2012;33:2451\u20132468. doi: 10.1002/jcc.23067.", "ArticleIdList": ["10.1002/jcc.23067", "PMC3477297", "22821581"]}, {"Citation": "Vanommeslaeghe K., Hatcher E., Acharya C., Kundu S., Zhong S., Shim J., Darian E., Guvench O., Lopes P., Vorobyov I., et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 2010;31:671\u2013690. doi: 10.1002/jcc.21367.", "ArticleIdList": ["10.1002/jcc.21367", "PMC2888302", "19575467"]}, {"Citation": "Boonstra S., Onck P.R., Giessen E.v.d. CHARMM TIP3P Water Model Suppresses Peptide Folding by Solvating the Unfolded State. J. Phys. Chem. B. 2016;120:3692\u20133698. doi: 10.1021/acs.jpcb.6b01316.", "ArticleIdList": ["10.1021/acs.jpcb.6b01316", "27031562"]}, {"Citation": "Kuang Z., Luginsland J., Thomas R.J., Dennis P.B., Kelley-Loughnane N., Roach W.P., Naik R.R. Molecular dynamics simulations explore effects of electric field orientations on spike proteins of SARS-CoV-2 virions. Sci. Rep. 2022;12:12986. doi: 10.1038/s41598-022-17009-1.", "ArticleIdList": ["10.1038/s41598-022-17009-1", "PMC9334739", "35906467"]}]}], "History": [{"Year": "2023", "Month": "10", "Day": "13"}, {"Year": "2024", "Month": "2", "Day": "4"}, {"Year": "2024", "Month": "2", "Day": "14"}, {"Year": "2024", "Month": "3", "Day": "14", "Hour": "6", "Minute": "46"}, {"Year": "2024", "Month": "3", "Day": "13", "Hour": "6", "Minute": "46"}, {"Year": "2024", "Month": "3", "Day": "13", "Hour": "1", "Minute": "26"}, {"Year": "2024", "Month": "2", "Day": "25"}], "PublicationStatus": "epublish", "ArticleIdList": ["38474509", "PMC10934083", "10.3390/molecules29050998", "molecules29050998"]}}]}